Navigation Links
Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
Date:9/5/2007

ANN ARBOR, Mich., Sept. 6 /PRNewswire/ -- Terumo Heart Inc. announced today that it is planning a European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland on September 17, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO

http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

A summary of the European Clinical Trial results for the company's DuraHeart(TM) Left Ventricular Assist System (LVAS) will be presented by Dr. Aly El-Banayosy from the Heart Center Nordrhine-Westaflen, Bad Oeynhausen, Germany. This will be followed by a presentation from Dr. Eric Rose, Professor of Surgery at Columbia University Medical Center in New York, entitled "The Emerging New Era of Mechanical Circulatory Support".

The EACTS meeting will mark the official launch of the DuraHeart LVAS. The device has been on the market in Europe for several months and is experiencing significant interest since achieving a CE Mark earlier in the year.

The DuraHeart LVAS is a 3rd generation circulatory support device with full magnetic levitation, intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is the only approved implantable Left Ventricular Assist System combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. The DuraHeart System is not available in the United States.

Terumo Heart Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for the heart failure patient. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products.

Contact: Mark White, Marketing Manager, Terumo Heart Inc., Ann Arbor, Michigan, USA on (734) 741-6262 or mark.white@terumomedical.com.


'/>"/>
SOURCE Terumo Heart Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2019)... ... December 02, 2019 , ... Today asensei, Feed.fm, Mux ... a complete solution for digital fitness experience creators. , As more and more Connected ... companies can differentiate their products and decrease time to market. This partnership was forged ...
(Date:11/30/2019)... (PRWEB) , ... November 29, 2019 , ... In the ... time. With countless awards, reviews, and media, there is no shortage of phenomenal restaurants ... of the most exceptional talent in the world. Christian Bowman, Chef to NBA All-Stars ...
(Date:11/27/2019)... ... , ... Home sales continue to be very robust at Wickenburg Ranch, and they are excited ... Homesite 266 to Jim and Sue. Jim is a native Texan, and Sue grew up ... start their next chapter at Wickenburg Ranch away from the Scottsdale traffic. They are most ...
Breaking Medicine Technology:
(Date:12/4/2019)... COLLEGE STATION, Texas (PRWEB) , ... December 04, 2019 , ... ... be a time of physical and mental stress, said Texas A&M AgriLife Extension Service ... make during the holidays to lower stress and benefit your overall wellness,” said Joyce ...
(Date:12/4/2019)... ... December 04, 2019 , ... Eolas ... for treating tobacco use and dependence. The study will investigate safety and pharmacokinetics ... penetrant antagonist of orexin-1 (hypocretin-1) receptors that is being developed in collaboration with ...
(Date:12/2/2019)... ... December 02, 2019 , ... TrialScope, the global leader in ... North American branch of the healthcare business of Merck KGaA, Darmstadt, Germany, to ... and inform patients, caregivers, the public, patient advocacy groups and healthcare professionals (HCPs) ...
(Date:12/2/2019)... ... December 02, 2019 , ... ... and flexibility to the Sterile Processing Department. The elegant design provides a smooth ... P1000 has downward sliding doors that allow for manual loading that provides high ...
(Date:11/30/2019)... ... November 28, 2019 , ... Planet 13 , ... production and dispensary operations, has received a Clio Cannabis Award in Brand Design ... a great accomplishment for our company and also for the talented creative team ...
Breaking Medicine News(10 mins):